Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 802-812

  Gully, Danielle ^a   Labeeuw, Bernard ^a   Boigegrain, Robert ^a   Oury Donat, Florence ^a   Bachy, André ^a   Poncelet, Martine ^a   Steinberg, Régis ^a   Suaud Chagny, Marie Françoise ^b   Santucci, Vincent ^a   Vita, Natalio ^a   Pecceu, Florence ^a   Labbé Jullié, Catherine ^c   Kitabgi, Patrick ^c   Soubrié, Philippe ^a   Le Fur, Gérard ^a   Maffrand, Jean Pierre ^a  

^a SANOFI   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; ACETYLCHOLINE; DOPAMINE; INOSITOL PHOSPHATE; NEUROTENSIN; NEUROTENSIN RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANALGESIA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CALCIUM MOBILIZATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GUINEA PIG; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADAMANTANE; ANIMALS; AXONAL TRANSPORT; BINDING SITES; BRAIN; CALCIUM; CELL LINE; CELL MEMBRANE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; DOPAMINE; FEMALE; HUMANS; IMIDAZOLES; INOSITOL PHOSPHATES; MALE; MICE; MICE, INBRED STRAINS; NEURONS; NEUROTENSIN; NUCLEUS ACCUMBENS; RATS; RATS, INBRED STRAINS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; RECOMBINANT PROTEINS; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TRANSFECTION;

EID: 14444284838     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. AMAR, S., KITABGI, P. AND VINCENT, J. P.: Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonie adenocarcinoma cell line HT 29. FEBS Lett. 20: 31-36, 1986.
2. 3H]SR 48692, in the guinea-pig brain. J. Pharmacol. Exp. Ther. 273: 1350-1358, 1995.
3. BISSETTE, G., NEMEROFF, C. B., LOOSEN, P. T. AND PRANGE, A. J.: Hypothermia and cold intolerance induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (Lond.) 262: 607-609, 1976.
4. Bozou, J. C., ROCHET, N., MAGNALDO, I., VINCENT, J. P. AND KITABGI P.: Neurotensin stimulates inositol triphosphate-mediated calcium mobilization but not protein kinase C activation in HT 29 cells. Biochem. J. 264: 871-878, 1989.
5. BRADFORD, M. M.: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. J. Biol. Chem. 261: 1487-1490, 1976.
6. BUNNEY, B. S., CHIODO, L. A. AND GRACE, A. A.: Midbrain dopamine system electrophysiological functioning: A review and new hypothesis. Synapse 9: 79-94, 1991.
7. BUNNEY, B. S. AND GRACE, A. A.: Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci. 23: 1715-1728, 1978.
8. BURGEVIN, M. C., CASTEL, M. N., QUARTERONET, D., CHEVET, T. AND LADURON, P. M.: Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience 49: 627-633, 1992.
9. CARRAWAY, R. E. AND LEEMAN, S. E.: The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248: 6854-6861, 1973.
10. CARRAWAY, R. E. AND LEEMAN, S. E.: Characterization of radioimmunoassayable neurotensin in the rat. J. Biol. Chem. 251: 7045-7052, 1976.
11. CASTEL, M. N., BEAUDET, A. AND LADURON, P.: Retrograde axonal transport of neurotensin in rat nigrostriatal dopaminergic neurons. Biochem. Pharmacol. 47: 53-62, 1994.
12. CHAKRAVARTY, P. K., CHEN, A., NAYLOR, E. M., RANSOM, R. W., SCHNECK, K. A. AND CLINESCHMIDT, B. V.: Phthalazinone biphenyl acylsulfonamides: A new class of non-peptide neurotensin antagonists. In Proceedings of the 206th American Chemical Society National Meeting, August 22-27, Chicago, IL, p. MEDI 198, American Chemical Society, Washington DC, 1993.
13. CHALON, P., VITA, N., KAGHAD, M., GUILLEMOT, M., BONNIN, J., DELPECH, B., LE FUR, G., FERRARA, P. AND CAPUT, D.: Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386: 91-94, 1996.
14. CHERMAT, R. AND SIMON, P.: Injection intraventriculaire cérébrale chez le rat non anesthésié (Fiche Technique, no. 38). J. Pharmacol. (Paris) 4: 489-492, 1975.
15. CHIODO, L. A. AND BUNNEY, B. S.: Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5: 2539-2544, 1985.
16. CLINESCHMIDT, B, V., MCGUFFIN, J. C. AND BUNTING, P. B.: Neurotensin: Antinocisponsive action in rodents. Eur. J. Pharmacol, 54: 129-139, 1979.
17. COQUEREL, A., DUBUC, I., KITABGI, P. AND COSTENTIN, J.: Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin N. Neurochem. Int. 12: 361-366, 1988.
18. CRAIG, D. A.: The Cheng-Prusoff relationship: Something lost in the translation. Trends Pharmacol. Sci. 14: 89-98, 1993.
19. CUSACK, B., MCCORMICK, D. J., PANG, Y. P., SOUDER, P., GARCIA, R., FAUQ, A. AND RICHELSON, E.: Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereo-selectivity and superagonism. J. Biol. Chem. 270: 18359-18366, 1995.
20. DUBUC, I., COSTENTIN, J., TERRANOVA, J. P., BARNOUIN, M. C., SOUBRIÉ, P., LE FUR, G., ROSTÈNE, W. AND KITABGI, P.: The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharmacol. 112: 352-354, 1994.
21. ERVIN, G. N. AND NEMEROFF, C. B.: Interactions of neurotensin with dopamine-containing neurons in the central nervous system. Prog. Neuropsychopharmacol. Biol. Psychiatry 12: S53-S69, 1988.
22. FAURE, M. P., NOVEL, D., ALONSO, R. AND ST. PIERRE, J. A.: Confocal microscopic characterization of neurotensin internalization in cultured neurons and glial cells. Soc. Neurosci. Abstr. 20: suppl. 1, 514, 1994.
23. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3450, 1985.
24. GULLY, D., CANTON, M., BOIGEGRAIN, R., JEANJEAN, F., MOLIMARD, J. C., PONCELET, M., GUEUDET, C., HEAULME, M., LEYRIS, R., BROUARD, A., PELAPRAT, D., LABBÉ-JUILLIÉ, C., MAZELLA, J., SOUBRIÉ, P., M AFFRAND, J. P., ROSTÈNE, W., KITABGI, P. AND LE FUR, G.: Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U.S.A. 90: 65-69, 1993.
25. HALEY, T. J. AND MCCORMICK, W. G.: Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. 12: 12-15, 1957.
26. HERMANS, E., GAILLY, P., OCTAVE, J. N. AND MALOTEAUX, J. M.: Rapid desensitization of agonist-induced calcium mobilization in transfected PC12 cells expressing the rat neurotensin receptor. Biochem. Biophys. Res. Commun. 198: 400-407, 1994.
27. JOLAS, T. AND AGHAJANIAN, G. K.: Neurotensin excitation of serotoninergic neurons in the dorsal raphe nucleus of the rat in vitro. Eur. J. Neurosci. 8: 153-161, 1996.
28. 3H]neurotensin in human brain: Properties and distribution. J. Neurochem. 46: 946-952, 1986.
29. KASCKOW, J. AND NEMEROFF, C. B.: The neurobiology of neurotensin: Focus on NT-DA interactions. Regul. Pept. 36: 153-164, 1991.
30. KESTEN, S. R., AKUNNE, H., JOHNSON, S. J., WISE, L. D. AND WUSTROW, D. J.: Novel small molecule neurotensin antagonists. In Proceedings of the 24th National Medicinal Chemistry Symposium, June 21-25, Salt Lake City, UT, p. 74, 1994.
31. KITABGI, P.: Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem. Int. 14: 111-119, 1989.
32. KITABGI, P., CHECLER, F., MAZELLA, J. AND VINCENT, J. P.: Pharmacology and biochemistry of neurotensin receptors. Rev. Clin. Basic Pharmacol. 5: 397-486, 1985.
33. KITABGI, P., ROSTÈNE, W., DUSSAILLANT, M., SCHOTTE, A., LADURON, P. M. AND VINCENT, J. P.: Two populations of neurotensin binding sites in murine brain: Discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur. J. Pharmacol. 140: 285-293, 1987.
34. 3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol. Pharmacol. 47: 1050-1056, 1995.
35. LABBÉ-JUILLIÉ, C., BROUARD, A., DOULUT, S., BOURDEL, E., PELAPRAT, D., MAZELLA, J., MARTINEZ, J., ROSTÈNE, W., COSTENTIN, J. AND KITABGI, P.: In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. J. Pharmacol. Exp. Ther. 268: 328-336, 1994.
36. MAZELLA, J., LEONARD, K., CHABRY, J., KITABGI, P., VINCENT, J. P. AND BEAUDET, A.: Binding and internalization of iodinated neurotensin in neuronal cultures from embryonic mouse brain. Brain Res. 564: 249-255, 1991.
37. MEREU, G., LILLIU, V., VARGIU, P., MUNTONI, A. L., DIANA, M. AND CESSA, G. L.: Depolarization inactivation of dopamine neurons: An artifact? J. Neurosci. 15: 1144-1149, 1995.
38. MINABE, Y., EMORI, K., TOOR, A., STUTZMANN, G. E. AND ASHBY, C. R., JR.: The effect of the acute and chronic administration of CP 96,345, a selective neurokinin receptor antagonist, on midbrain dopamine neurons in the rat: A single unit, extracellular recording study. Synapse 22: 35-45, 1996.
39. MUNSON, P. J. AND RODBARD, D.: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 220-239, 1980.
40. MYERS, R. D. AND LEE, T. F.: Neurotensin perfusion of rat hypothalamus: Dissociation of dopamine release from body temperature change. Neuroscience 12: 241-253, 1984.
41. NAYLOR, E. M., CHAKRAVARTY, P. K., CHEN, A., RANSOM, R. W. AND SCHNECK, K. A.: Potent nonpeptidic neurotensin antagonists: Quinazolinone biphenyl acyl sulfonamides. In Proceedings of the 206th American Chemical Society National Meeting, August 22-27, Chicago, IL, p. MEDI 197, American Chemical Society, Washington DC, 1993.
42. NEMEROFF, C. B. AND CAIN, S. T.: Neurotensin-dopamine interactions in the CNS. Trends Pharmacol. Sci. Rev. 201-205, 1985.
43. NEMEROFF, C. B., LUTTINGER, D. AND PRANGE, A. J.: Neurotensin: Central nervous system effects of a neuropeptide. Trends Neurosci. 3: 212-215, 1980.
44. OURY-DONAT, F., HEAULME, M., THURNEYSSEN, O., GONALONS, N., GULLY, D., LE FUR, G. AND SOUBRIÉ, P.: Biochemical characterization of SR 48692, a selective non-peptide antagonist of the neurotensin receptor. Br. J. Pharmacol 112: suppl., 240P, 1995.
45. PAXINOS, G. AND WATSON, C.: The rat brain in stereotaxic coordinates. Academic Press, Sydney, 1982.
46. PHILLIPS, A. G., BLAHA, C. D., FIBIGER, H. C. AND LANE, R. F.: Interactions between mesolimbic dopamine neurons, cholecystokinin, and neurotensin: Evidence using in vitro voltammetry. Ann. N.Y. Acad. Sci. 537: 347-361, 1988.
47. PONCELET, M., GUEUDET, C., GULLY, D., SOUBRIÉ, P. AND LE FUR, G.: Turning behavior induced by intrastriatal injection of neurotensin in mice: Sensitivity to non-peptide neurotensin antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 349: 57-60, 1994a.
48. PONCELET, M., SANTUCCI, V., PAUL, R., GUEUDET, C., LAVASTRE, S., GUITARD, J., STEINBERG, R., TERRANOVA, J. P., BRELIERE, J. C., SOUBRIÉ, P. AND LE FUR, G.: Neuropharmacological profile of a novel and selective ligand of the sigma site. Neuropharmacology 32: 605-615, 1993.
49. PONCELET, M., SOUILHAC, J., GUEUDET, C., TERRANOVA, J. P., GULLY, D., LE FUR, G. AND SOUBRIÉ, P.: Effect of SR 48692, a selective non peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats. Psychopharmacology 116: 237-241, 1994b.
50. 3H]neurotensin binding sites in rat brain. Brain Res. 408: 326-328, 1987.
51. SNIDER, R. M., PEREIRA, D. A. AND LONGO, K. P.: UK-73,093: A non-peptide neurotensin receptor antagonist. Biorg. Med. Chem. Lett. 2: 1534-1540, 1992.
52. STEINBERG, R., BOUGAULT, I. M., SOUILHAC, J., GULLY, D., LE FUR, G. AND SOUBRIÉ, P.: Blockade of neurotensin receptors by the antagonist SR 48692 partially prevents retrograde axonal transport of neurotensin in rat nigrostriatal system. Neurosci. Lett. 166: 106-118, 1994a.
53. STEINBERG, R., BRUN, P., FOURNIER, M., SOUILHAC, J., RODIER, D., MONS, G., TERRANOVA, J. P., LE FUR, G. AND SOUBRIÉ, P.: SR 48692, a non-peptide neurotensin receptor antagonist, differentially affects neurotensin-induced behavior and changes in dopaminergic transmission. Neuroscience 59: 921-929, 1994b.
54. STEINBERG, R., RODIER, R., MONS, G., GULLY, D., LE FUR, G. AND SOUBRIÉ, P.: SR 48692-sensitive neurotensin receptors modulate acetylcholine release in the rat striatum. Neuropeptides 29: 27-31, 1995.
55. SUAUD-CHAGNY, M. F., CHERGUI, K., CHOUVET, G. AND GONON, F.: Relationship between dopamine release in the rat nucleus accumbens and the discharge activity of dopaminergic neurons during local in vivo application of amino acids in the ventral tegmental area. Neuroscience 49: 63-72, 1992.
56. TANAKA, K., MASSU, M. AND NAKANISHI, S.: Structure and functional expression of the cloned rat neurotensin receptors. Neuron 4: 847-854, 1990.
57. VITA, N., LAURENT, P., LEFORT, S., CHALON, P., DUMONT, X., KAGHAD, M., GULLY, D., LE FUR, G., FERRARA, P. AND CAPUT, D.: Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 317: 139-142, 1993.